drugset
drugset / Trial / NCT04422496

The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects

NCT04422496 ↗

Phase 1 Completed 73 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Non-alcoholic fatty liver disease (NAFLD) treatment drug HEC96719 in Healthy Male and Female Subjects

Timeline

Start
2020-08-10
Primary completion
2021-02-23
Completion
2021-02-23

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC96719 Unknown 0.2 mg Oral
Subject HEC96719 Unknown 0.5 mg Oral
Subject HEC96719 Unknown 1 mg Oral
Subject HEC96719 Unknown 2 mg Oral
Subject HEC96719 Unknown 3 mg Oral
Subject HEC96719 Unknown 4 mg Oral

Indications

NAFLD1 metabolic dysfunction-associated steatohepatitis